SLC1A2 and amyotrophic lateral sclerosis: This highlights the therapeutic potential of the YAP/Wnt/β-catenin/EAAT2 signaling pathway in delaying and treating ALS diseases, which may contribute to the development of new therapeutic methods for ALS.